DE60019166D1 - Verwendung von adatanserin zur behandlung von akuten neurodegenerativen erkrankungen - Google Patents
Verwendung von adatanserin zur behandlung von akuten neurodegenerativen erkrankungenInfo
- Publication number
- DE60019166D1 DE60019166D1 DE60019166T DE60019166T DE60019166D1 DE 60019166 D1 DE60019166 D1 DE 60019166D1 DE 60019166 T DE60019166 T DE 60019166T DE 60019166 T DE60019166 T DE 60019166T DE 60019166 D1 DE60019166 D1 DE 60019166D1
- Authority
- DE
- Germany
- Prior art keywords
- adatanserin
- treatment
- neurodegenerative diseases
- acute neurodegenerative
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Processing Of Meat And Fish (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43921999A | 1999-11-12 | 1999-11-12 | |
US439219 | 1999-11-12 | ||
PCT/US2000/030973 WO2001034136A2 (en) | 1999-11-12 | 2000-11-10 | Use of adatanserin for the treatment of neurodegenerative conditions |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60019166D1 true DE60019166D1 (de) | 2005-05-04 |
DE60019166T2 DE60019166T2 (de) | 2006-05-11 |
Family
ID=23743796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60019166T Expired - Fee Related DE60019166T2 (de) | 1999-11-12 | 2000-11-10 | Verwendung von adatanserin zur behandlung von akuten neurodegenerativen erkrankungen |
Country Status (22)
Country | Link |
---|---|
EP (2) | EP1547597A3 (de) |
JP (1) | JP2003513915A (de) |
KR (1) | KR100757226B1 (de) |
CN (1) | CN100469368C (de) |
AT (1) | ATE291919T1 (de) |
AU (1) | AU773733B2 (de) |
BR (1) | BR0015523A (de) |
CA (1) | CA2390797A1 (de) |
CZ (1) | CZ298535B6 (de) |
DE (1) | DE60019166T2 (de) |
EA (1) | EA006099B1 (de) |
ES (1) | ES2235998T3 (de) |
HK (1) | HK1046505B (de) |
HU (1) | HUP0301847A3 (de) |
IL (1) | IL149264A0 (de) |
MX (1) | MXPA02004654A (de) |
NO (1) | NO322371B1 (de) |
NZ (1) | NZ518814A (de) |
PL (1) | PL355014A1 (de) |
PT (1) | PT1242089E (de) |
WO (1) | WO2001034136A2 (de) |
ZA (1) | ZA200204682B (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2390797A1 (en) * | 1999-11-12 | 2001-05-17 | Wyeth | Methods for the treatment and prevention of neurodegenerative conditions |
WO2009082268A2 (ru) | 2007-12-21 | 2009-07-02 | Alla Chem, Llc | ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5441961A (en) * | 1992-08-27 | 1995-08-15 | Eli Lilly And Company | Substituted cyclo or bicycloalkylamides of (8β)-6-(substituted) ergolines |
US5877173A (en) * | 1996-08-28 | 1999-03-02 | Washington University | Preventing neuronal degeneration in Alzheimer's disease |
US5902815A (en) * | 1996-09-03 | 1999-05-11 | Washington University | Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction |
CA2390797A1 (en) * | 1999-11-12 | 2001-05-17 | Wyeth | Methods for the treatment and prevention of neurodegenerative conditions |
-
2000
- 2000-11-10 CA CA002390797A patent/CA2390797A1/en not_active Abandoned
- 2000-11-10 EP EP05001510A patent/EP1547597A3/de not_active Withdrawn
- 2000-11-10 AT AT00979157T patent/ATE291919T1/de not_active IP Right Cessation
- 2000-11-10 JP JP2001536136A patent/JP2003513915A/ja not_active Withdrawn
- 2000-11-10 IL IL14926400A patent/IL149264A0/xx unknown
- 2000-11-10 CZ CZ20021629A patent/CZ298535B6/cs not_active IP Right Cessation
- 2000-11-10 HU HU0301847A patent/HUP0301847A3/hu unknown
- 2000-11-10 WO PCT/US2000/030973 patent/WO2001034136A2/en active IP Right Grant
- 2000-11-10 NZ NZ518814A patent/NZ518814A/en unknown
- 2000-11-10 DE DE60019166T patent/DE60019166T2/de not_active Expired - Fee Related
- 2000-11-10 EA EA200200559A patent/EA006099B1/ru not_active IP Right Cessation
- 2000-11-10 CN CNB008156085A patent/CN100469368C/zh not_active Expired - Fee Related
- 2000-11-10 KR KR1020027006067A patent/KR100757226B1/ko not_active IP Right Cessation
- 2000-11-10 AU AU16567/01A patent/AU773733B2/en not_active Ceased
- 2000-11-10 MX MXPA02004654A patent/MXPA02004654A/es active IP Right Grant
- 2000-11-10 EP EP00979157A patent/EP1242089B1/de not_active Expired - Lifetime
- 2000-11-10 PL PL00355014A patent/PL355014A1/xx not_active IP Right Cessation
- 2000-11-10 ES ES00979157T patent/ES2235998T3/es not_active Expired - Lifetime
- 2000-11-10 BR BR0015523-3A patent/BR0015523A/pt not_active Application Discontinuation
- 2000-11-10 PT PT00979157T patent/PT1242089E/pt unknown
-
2002
- 2002-05-07 NO NO20022187A patent/NO322371B1/no not_active IP Right Cessation
- 2002-06-11 ZA ZA200204682A patent/ZA200204682B/en unknown
- 2002-11-08 HK HK02108123.1A patent/HK1046505B/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69230046T2 (de) | 2-Bromomelatonin zur Behandlung von Schlafstörungen | |
ATE450269T1 (de) | Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten | |
DE69333321D1 (de) | Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten. | |
BR0115166A (pt) | Combinações de drogas (por exemplo, cloropromazina e pentamidina) para o tratamento de distúrbios neoplásticos | |
ATE175348T1 (de) | L - deprenyl zur behandlung von makulärer degeneration | |
DK0668763T3 (da) | Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme | |
DE60115432D1 (de) | Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen | |
ATE366581T1 (de) | Apoptotische körper zur verwendung in der behandlung von neurodegenerativen und sonstigen nervenerkrankungen | |
DE69939075D1 (de) | Pharmazeutische Zusammenstellung zur Vorbeugung und Behandlung von mit Zellkrankheiten des Augenhintergrundes zusammenhängenden Krankheiten | |
ATE285773T1 (de) | Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten | |
ATE291919T1 (de) | Verwendung von adatanserin zur behandlung von akuten neurodegenerativen erkrankungen | |
NO971453D0 (no) | Anvendelse av bradykinin-antagonister for fremstilling av legemidler for behandling av kroniske fibrogenetiske og akutte leversykdommer | |
DE69307702T2 (de) | Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit | |
DE69733321D1 (de) | Olanzapine zur behandlung von drogenmissbrauch | |
DE69430807D1 (de) | Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen | |
DE60122781D1 (de) | Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen | |
RU94013606A (ru) | Гемостимулятор | |
RU95117774A (ru) | Способ лечения хронических воспалительных заболеваний верхних дыхательных путей | |
RU97110384A (ru) | Способ лечения вибрационной болезни |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |